TAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Takeda Pharmaceutical Co Ltd (TAK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive drug development progress, and favorable options sentiment outweigh the lack of immediate trading signals and technical weakness.
The MACD is negative and expanding (-0.181), indicating bearish momentum. RSI is neutral at 30.928, and moving averages are converging, suggesting indecision. The stock is trading near a key support level (S1: 17.732), which could act as a potential entry point.
FDA Priority Review for Rusfertide's New Drug Application, which could drive future revenue growth.
Strong Q3 financial performance with significant YoY growth in revenue (+4.16%), net income (+335.66%), and EPS (+337.08%).
Positive sentiment from analysts regarding Takeda's partnership with Xoma.
Layoff of 400 employees in the U.S., which may raise concerns about operational restructuring.
Bearish technical indicators, including a negative MACD and neutral RSI, suggesting short-term weakness.
In Q3 2026, Takeda reported strong financial growth: Revenue increased by 4.16% YoY to 1.19 trillion, Net Income surged by 335.66% YoY to 103.64 billion, EPS rose by 337.08% YoY to 65.65, and Gross Margin improved by 5.94% YoY to 54.91%.
Analysts maintain a positive outlook on Takeda's partnership with Xoma, citing the depth and creativity of its pipeline. This is reflected in H.C. Wainwright's Buy rating for Xoma, which indirectly highlights Takeda's strengths.
